Sofosbuvir: all 175 studies that test it
Page 2 of 2. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard TreatmentCompletedNCT04530422Phase 3
- Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19CompletedNCT04498936Phase 4
- Sofosbuvir Containing Regimens in Treatment of COVID 19 PatientsStatus unknownNCT04497649Phase 2/3
- Sofosbuvir in Treatment of COVID 19Status unknownNCT04460443Phase 2/3
- Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19Status unknownNCT04443725Phase 2/3
- Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian PatientsCompletedNCT04385407Phase 2
- A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy VolunteersCompletedNCT04358523Phase 1
- PK of SOF/LED in HCV - Infected Adolescents With Haematological DisordersStatus unknownNCT04353986Phase 3
- Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1CompletedNCT04246723Phase 2
- The Renal Safety in Patients With Chronic HCV Undergoing Sofosbuvir Containing Antiviral TherapyStatus unknownNCT04169464Phase 4
- Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection PatientsStatus unknownNCT04111367Phase 2
- Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in BrazilStatus unknownNCT04039698Not applicable
- Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection PatientsStatus unknownNCT04001608Phase 3
- KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis CCompletedNCT03995485Phase 3
- Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject DrugsTerminatedNCT03981211Not applicable
- Safety of Sofosbuvir in People With Advanced Kidney FailureCompletedNCT03883698Phase 3
- Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients SeraStatus unknownNCT03882307Early Phase 1
- Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/VelpatasvirCompletedNCT03818308Phase 2
- The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant RecipientsActive, not recruitingNCT03809533Phase 2
- Management of Decompensated HCV Cirrhotic PatientsCompletedNCT03547895Not applicable
- Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C VirusStatus unknownNCT03540212Phase 2/3
- DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)CompletedNCT03537196Phase 4
- A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgramsCompletedNCT03492112Not applicable
- Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab ModelStatus unknownNCT03488485Not applicable
- Phase 3 Study of Yimitasvir Phosphate CapsulesCompletedNCT03487107Phase 3
- Phase 2 Study of Yimitasvir Phosphate CapsulesCompletedNCT03458481Phase 2
- Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis CCompletedNCT03453346Not applicable
- Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis CCompletedNCT03416491Phase 2
- Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency VirusCompletedNCT03369327Phase 3
- Effect Of DAAs For Treatment Of HCV On Normal KidneyStatus unknownNCT03296930Phase 4
- HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)CompletedNCT03282474Phase 2
- Expanding the Pool in Orthotopic Heart TransplantationCompletedNCT03222531Phase 2
- Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 PatientsCompletedNCT03200184Phase 4
- Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus PatientsStatus unknownNCT03163849Phase 3
- A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5AWithdrawnNCT03105349Phase 4
- Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney TransplantWithdrawnNCT03093740Phase 4
- Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & DaclatasvirCompletedNCT03080415Phase 3
- Treating Hepatitis C in CRF Using Sofosbuvir and DaclatasvirCompletedNCT03063879Phase 4
- A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)CompletedNCT03062423Phase 1
- Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label TrialCompletedNCT03032666Phase 4
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionCompletedNCT02992457Phase 4
- Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric PatientsStatus unknownNCT02985281Phase 2/3
- Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing WorldCompletedNCT02964091Phase 4
- Strategic Transformation of the Market of HCV TreatmentsStatus unknownNCT02961426Phase 2/3
- A Bio-equivalence Study of Sofosbuvir From Magicbuvir 400 mg Film Coated Tablets ( Magic Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)CompletedNCT02953535Phase 1
- Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV InfectionCompletedNCT02836925Phase 2
- Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without InterferonCompletedNCT02804386Phase 4
- Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)CompletedNCT02768961Phase 4
- Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1CompletedNCT02705534Phase 3
- Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic PatientsCompletedNCT02702739Phase 4
- Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With SofosbuvirCompletedNCT02647632Phase 2
- Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution TherapyStatus unknownNCT02638233Phase 4
- Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)CompletedNCT02624063Phase 4
- A Bio-equivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & Sovaldi 400 mg Film Coated Tablets (Gilead Sciences, United Kingdom)CompletedNCT02605798Phase 1
- Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) CirrhoticsCompletedNCT02596880Phase 3
- Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected PatientsCompletedNCT02576314Phase 3
- A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)WithdrawnNCT02556086Phase 2
- DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)CompletedNCT02555943Phase 2/3
- A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)CompletedNCT02491450Phase 1
- Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1WithdrawnNCT02485080Phase 4
- Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected PatientsCompletedNCT02482077Phase 4
- Neutrino Regimen for Treatment-experienced HCV GT1 PatientsCompletedNCT02480686Phase 4
- Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infectionCompletedNCT02480387Phase 2
- Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)TerminatedNCT02478229Phase 3
- SOF Plus DCV in Treating Chinese Treatment-experienced HCV PatientsCompletedNCT02473211Phase 2/3
- Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b SubjectsCompletedNCT02470858Phase 2
- Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral TherapyStatus unknownNCT02469012Not applicable
- A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug UseCompletedNCT02336139Phase 2
- An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT02278419Phase 2
- Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT02253550Phase 2
- A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis CWithdrawnNCT02206932Phase 4
- DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)CompletedNCT02156570Phase 4
- Surveillance and Treatment of Prisoners With Hepatitis CCompletedNCT02064049Phase 4
- Open-Label Hepatic Impairment StudyCompletedNCT01497327Phase 1
- Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C InfectionCompletedNCT01435044Phase 2